Michelle Dagostine, MD
Neurology · Cheshire, CTNPI 1205086733
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $200,429 of the $239,478 with a category attached, or 83.7%. 21 manufacturers reported payments, led by Adamas Pharmaceuticals, Inc. at 38.9% of the total. Reporting peaked in 2019 at $91,236 and has fallen 99.2% since, to $716 in 2025. Among neurology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $628.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adamas Pharmaceuticals, Inc.$93K
- Neurocrine Biosciences, Inc.$76K
- UCB, Inc.$18K
- Boston Scientific$16K
- Lundbeck LLC$15K
- MDD US Operations, LLC$7K
- plus $14K from 15 others
Across 3 payments — averaging $575.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Consulting fees$19,3008%
- Speaking & faculty fees$200,42984%
- Travel & lodging$15,3426%
- Food & beverage$4,4062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adamas Pharmaceuticals, Inc. | 103 | $93,268 |
| Neurocrine Biosciences, Inc. | 61 | $76,062 |
| UCB, Inc. | 37 | $18,325 |
| Boston Scientific | 20 | $15,750 |
| Lundbeck LLC | 22 | $14,913 |
| MDD US Operations, LLC | 34 | $7,450 |
| AbbVie(2 entities) | 45 | $7,439 |
| Medtronic(2 entities) | 20 | $3,909 |
| Acadia Pharmaceuticals Inc | 3 | $1,626 |
| Supernus Pharmaceuticals, Inc. | 11 | $170 |
| Teva Pharmaceuticals USA, Inc. | 7 | $152 |
| Amneal Pharmaceuticals LLC | 3 | $102 |
| Arbor Pharmaceuticals, Inc. | 4 | $71 |
| Abbott | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| Johnson & Johnson | 1 | $28 |
| Amgen | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Biogen | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$239,478 in reported general payments places this provider in the 90th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 48 | $257,510 |
| GocovriAmantadine Hcl | 45 | $217,207 |
| NourianzIstradefylline | 54 | $144,346 |
| IngrezzaValbenazine Tosylate | 16 | $137,277 |
| RytaryCarbidopa/Levodopa | 68 | $126,209 |
| OngentysOpicapone | 45 | $58,715 |
| NeuproRotigotine | 22 | $31,070 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 347 | $12,218 |
| OzempicSemaglutide | 11 | $10,480 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 35 | $9,266 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 171 | $6,731 |
| AmantadineAmantadine Hcl | 57 | $4,927 |
| Rasagiline Mesylate | 30 | $3,873 |
| Pramipexole ErPramipexole Di-Hcl | 14 | $3,569 |
| Rivastigmine | 12 | $3,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,626 | $257,51048 claims |
| MDD US Operations, LLCGocovri | $7,450 | $217,20745 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $76,062 | $195,99361 claims |
| Kyowa Kirin, Inc.Nourianz | $26 | $144,34654 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $102 | $126,87779 claims |
| UCB, Inc.Neupro | $18,325 | $31,07022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 280 neurology providers in Connecticut.
Other neurology in Cheshire
- Duarte MachadoCheshire$426K
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Tanya BilchikEast Hartford$361K
- Peter GottschalkFairfield$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.